leisure time -WSS

leisure time

author：focus 2025-09-27 10:02:42 - browse：7537

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Adam's Biotech Scorecard: Do Sarepta's exon

WSS

DeSantis can now import cheaper drugs. But will Biden get credit?

Adam's Biotech Scorecard: Do Sarepta's exon

Doulas covered by Medicaid under New York's new plan

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Three issues to watch in global health in 2024

New Medicare drug pricing powers could soon be upended in court

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Peter Hotez and the public health issue of online harassment

Adam's Biotech Scorecard: Do Sarepta's exon

DIEP, the 'gold standard' of breast reconstruction, is under threat

Health insurers say they are turning to AI to cut costs, improve care

Guidelines to prevent youth baseball injuries need more muscle

Idaho abortion case may prompt more restrictions in other states

Medical records are filled with copy

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Wikipedia

Idaho abortion case may prompt more restrictions in other states

New menopause drug shows promise in relief for hot flashes

Risky weight loss products often used by teens globally, per study

Three issues to watch in global health in 2024

As JPM 2024 winds down, some health tech firms project optimism

Dark money group runs ads on China biotech bill

entertainment

Wikipedia

explore

hotspot